Ventripoint Receives Further Funding From National Research Council of Canada

Ventripoint Diagnostics (TSXV: VPT) this morning had a brief release, indicating the firm has received further research funding. The latest round of funding comes from the National Research Council of Canada’s Industrial Research Assistance Program.

The recent funding has seen the firm receive an additional $107,000 in research and development funding, as well as certain advisory services. The grant is reportedly in addition to a recent funding for up to $120,000 that was previously granted.

Combined, the $227,000 in funding is expected to be used by the firm to enhance its VMS+ whole heart analysis system that is focused on changing how the analysis of the heart is conducted. The firm has indicated that its advisory board of cardiologists is eager to see the latest version of the project completed so as to be able to proceed with clinical field trials to verify the ability of the device to analyze whole heart function.

Commenting on the grant, CEO George Adams stated, “Ventripoint’s mission is to improve cardiac diagnosis for everyone, worldwide and especially for children, so it is wonderful to have the support of the Government of Canada through NRC IRAP as we push the limits of our technology to even better performance.”

Ventripoint Diagnostics last traded at $0.36 on the TSX Venture.


FULL DISCLOSURE: Ventripoint Diagnostics is a client of Canacom Group, the parent company of The Deep Dive. The company has been compensated to cover Ventripoint Diagnostics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. We may buy or sell securities in the company at any time.  Always do additional research and consult a professional before purchasing a security.

Video Articles

Fortune Bay: The Potential Billion Dollar Project

Japan Gold Enters New Chapter as Barrick Alliance Concludes – John Proust

Barrick Mining’s “Company Defining [Gold] Discovery”

Recommended

Nord Precious Metals Produces High Grade Silver Concentrate From Tailings

ESGold Secures $9 Million In Non-Dilutive Funding From Ocean Partners

Related News

VentriPoint Diagnostics: Corporate Overview

VentriPoint Diagnostics Ltd. (TSXV: VPT) is a small-cap medical device company that develops and commercializes...

Saturday, June 5, 2021, 05:25:00 PM

The Future Of 3D Heart Modeling – The Daily Dive feat George Adams

George Adams, CEO of Ventripoint Diagnostics (TSXV: VPT) joins our host Cassandra Leah today to...

Thursday, November 19, 2020, 01:00:00 PM

Ventripoint Enters Collaboration Agreement To Test Echocardiology Technology For Use With Canines

Ventripoint Diagnostics (TSXV: VPT) has entered into a new collaboration agreement as of this morning....

Monday, January 11, 2021, 09:21:12 AM

Ventripoint Installs Whole Heart Analysis System At Toronto General Hospital

Ventripoint Diagnostics (TSXV: VPT) has seen its technology installed at the largest cardiac centre in...

Thursday, November 5, 2020, 10:47:10 AM

Providing Echocardiography For Companion Animals – The Daily Dive feat George Adams of Ventripoint

Today on the Daily Dive is that of George Adams, CEO of Ventripoint Diagnostics (TSXV:...

Thursday, January 28, 2021, 01:30:00 PM